Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors

NCT03744468 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT03744468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03744468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors
Lead sponsor
BeiGene
Phase
Phase 1/2
Overall status
Completed
Start date
November 13, 2018
Completion date
February 6, 2025
Enrollment
147 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

hnscc for phase 2 dose expansion, locally advanced or metastatic solid tumors for phase 1, dose escalation and phase 2 safety lead-in, nsclc for phase 2 dose expansion